Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

ClinicalTrials.gov ID: NCT03325010

Public ClinicalTrials.gov record NCT03325010. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Study identification

NCT ID
NCT03325010
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
127 participants

Conditions and interventions

Interventions

  • Valbenazine Drug
  • Placebo oral capsule Drug

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 4, 2017
Primary completion
Oct 31, 2018
Completion
Nov 15, 2018
Last update posted
Jun 27, 2021

2017 – 2018

United States locations

U.S. sites
34
U.S. states
17
U.S. cities
30
Facility City State ZIP Site status
Neurocrine Clinical Site Sun City Arizona 85351
Neurocrine Clinical Site Rogers Arkansas 72758
Neurocrine Clinical Site Anaheim California 92805
Neurocrine Clinical Site San Diego California 92108
Neurocrine Clinical Site Santa Clarita California 91321
Neurocrine Clinical Site New Haven Connecticut 06519
Neurocrine Clinical Site Hialeah Florida 33012
Neurocrine Clinical Site Hialeah Florida 33013
Neurocrine Clinical Site Hialeah Florida 33018
Neurocrine Clinical Site Loxahatchee Groves Florida 33470
Neurocrine Clinical Site Orange City Florida 32763
Neurocrine Clinical Site Orlando Florida 32801
Neurocrine Clinical Site Orlando Florida 32803
Neurocrine Clinical Site Tampa Florida 33609
Neurocrine Clinical Site Chicago Illinois 60634
Neurocrine Clinical Site Chicago Illinois 60637
Neurocrine Clinical Site Naperville Illinois 60563
Neurocrine Clinical Site Iowa City Iowa 52242
Neurocrine Clinical Site Leawood Kansas 66206
Neurocrine Clinical Site Boston Massachusetts 02114
Neurocrine Clinical Site Lincoln Nebraska 68526
Neurocrine Clinical Site Nashua New Hampshire 03060
Neurocrine Clinical Site Mount Arlington New Jersey 07856
Neurocrine Clinical Site Voorhees Township New Jersey 08043
Neurocrine Clinical Site New York New York 10036
Neurocrine Clinical Site The Bronx New York 10467
Neurocrine Clinical Site Durham North Carolina 27705
Neurocrine Clinical Site Memphis Tennessee 38119
Neurocrine Clinical Site Dallas Texas 75243
Neurocrine Clinical Site Houston Texas 77058
Neurocrine Clinical Site Irving Texas 75062
Neurocrine Clinical Site Everett Washington 98201
Neurocrine Clinical Site Seattle Washington 98105
Neurocrine Clinical Site Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03325010, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 27, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03325010 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →